In NSCLC cell lines with wild-type p53, the drug gefitinib can activate apoptosis by increasing the presence of Fas at the cell membrane and restoring caspase activation, leading to increased TKI sensitivity. The gene discussed is TP53; the disease is non-small cell lung carcinoma.